HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Charnas, L. Articles by Orchard, P.J. Search for Related Content PubMed PubMed Citation Articles by Charnas, L. Articles by Orchard, P.J. Related Collections Related Articles

Reply to: Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report. Haematologica 2008; 93:e11–13

¹ Divisions of Hematology, Oncology, Blood and Marrow Transplantation and
² Clinical Neuroscience, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA
³ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA and
⁴ Department of Pediatrics, University Medical Center Eppendorf, Hamburg, Germany

We have read with interest and concern the recent case report¹ of a patient with metachromatic leukodystrophy (MLD) who underwent hematopoietic stem cell transplantation augmented with an infusion of donor-derived mesenchymal stem cells.

First of all, it is not clear that the patient had MLD. The standard diagnostic methods for diagnosis of MLD,² such as levels of urinary sulfatides and leukocyte arylsulfatase A (only urinary arylsulfatase A was detected in the low range), or mutation analysis of the arylsulfatase A gene have not been reported in this case. The pathological description of the peripheral nerve disease is uncommon for MLD. The MRI lesions of both grey and white matter, as described in this patient, are very unusual for adult MLD. Second, the report suggests that infusion of mesenchymal stem cells was important for the engraftment and for improvement of the peripheral nerve dysfunction. This is clearly a possibility, as suggested previously by Koc et al.,³ that warrants further investigations.

Since the diagnosis of MLD is questionable, however, these results are not interpretable.

The 40 months duration of survival after transplantation with stabilization alone is not evidence of therapeutic efficacy. It is necessary to say, that with the absence of the follow-up measures such as magnetic resonance imaging and neurophysiology evaluations it is impossible to state the potential efficacy of this approach. Treatment of rare metabolic diseases with stem cell transplantation requires a multidisciplinary approach for diagnosis, patient management, and outcome measures.

	References

TOP References

 

1. Meuleman N, Vanhaelen G, Tondreau T, et al. Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report. Haematologica 2008;93:e11-13.[Abstract/Free Full Text]
2. Von Figura K, Gieselmann V, Jaeken J. Metachromatic leukodystrophy - Metabolic and Molecular Basis of Inherited disease, New York: McGraw-Hill. 2001. p. 3695-724.
3. Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-22.[CrossRef][ISI][Medline]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Charnas, L. Articles by Orchard, P.J. Search for Related Content PubMed PubMed Citation Articles by Charnas, L. Articles by Orchard, P.J. Related Collections Related Articles